Supplying Honey to Clinical Buyers: What the Grade Actually Means

When clinical supply chain buyers source honey, they are not making a purchasing decision based on general quality claims or country of origin. They are sourcing a specific material to a specific grade, verified by a specific method, with batch-level documentation that supports their own compliance obligations downstream.

This post is written for buyers in clinical and wound care supply channels who need to understand how WA honey is graded, tested, and documented for supply at that level. It covers the grading framework, the verification method, the distinction between food grade and clinical grade supply, and the formats Honey X makes available to this buyer segment.

What "Medical Grade" Means in the Context of Honey Supply

The term "medical grade" in honey supply refers to a defined set of supply chain requirements, not a single property of the honey itself. It is the combination of independently verified antimicrobial activity at high Total Activity grades, batch-specific testing documentation, full traceability back to origin, and production under accredited quality systems.

Each of those requirements must be met simultaneously. A honey with high TA grading that lacks batch-specific documentation is not clinical-grade supply. A well-documented product from an accredited facility that has not been independently tested at the required TA threshold is equally unsuitable. Clinical supply buyers require all four elements to be present and verifiable.

Honey X supplies honey that meets all of these requirements. The supply is independently tested and third-party verified at Analytica (ALS) in New Zealand and ChemCentre in Western Australia, the laboratories most directly relevant to this verification standard.

The TA Grading Scale and What Clinical Buyers Look For

Total Activity (TA) is the primary metric for grading active WA honey. TA combines two distinct independently verified antimicrobial mechanisms: Peroxide Activity (PA), which is hydrogen peroxide-driven, and Non-Peroxide Activity (NPA), which is stable and not hydrogen-peroxide dependent.

The scale runs from TA10+ at moderate activity through TA20+, TA30+, TA40+, and TA50+ at elite grade. Honey X has achieved TA55+ as the highest grade verified in its supply.

Clinical supply chain buyers typically work with honey at TA30+ and above. At TA30+, the independently verified antimicrobial activity reaches the threshold considered meaningful for clinical supply purposes. Higher grades, TA40+ and TA50+, carry correspondingly higher documented activity levels. The buyer's own clinical protocols will determine the minimum TA threshold required for their specific application.

WDPE Testing: The Verification Method

The test method used to verify TA is the Well-Diffusion Phenol Equivalent (WDPE) assay. This is the accepted gold standard for measuring antimicrobial activity in honey, and it is the method used by Analytica (ALS) and ChemCentre, the labs Honey X uses for independent verification.

The WDPE method works as follows. Diluted honey is placed into a well in a petri dish with agar infused with Staphylococcus aureus bacteria. Over 24 hours, the antimicrobial compounds in the honey diffuse outward, inhibiting bacterial growth. The diameter of the bacteria-free zone is measured and compared against a phenol standard. The result is expressed as a TA grade: a TA30 result means the honey demonstrated the same antimicrobial activity as a 30% phenol solution under test conditions.

This is a quantified, reproducible, comparable result. It is not a subjective grading. All TA grades assigned to Honey X products are based on WDPE results from third-party independent testing. Honey X has conducted 153+ third-party tests across five laboratories, including Analytica (ALS), ChemCentre, and the University of Sydney. Batch-specific test certificates are available to approved buyers. Read more about how active WA honey is tested in the bioactivity testing overview.

Food Grade Versus Clinical Grade: The Supply Chain Distinction

Food grade honey meets food safety standards: HACCP compliance, absence of contaminants, correct moisture content, and standard traceability. That is the baseline for any reputable honey supply.

Clinical grade supply begins where food grade supply ends. The distinctions are in testing rigour, documentation depth, and batch traceability:

• Testing rigour: Clinical supply requires batch-specific WDPE results at defined TA thresholds. Food grade supply does not require antimicrobial activity testing.
• Documentation: Clinical supply buyers require certificates of analysis at the batch level, not the variety level. Each unit supplied must carry its own verified test result.
• Traceability: Clinical supply requires full traceability from hive location and harvest date through to the specific batch shipped. General food grade supply does not carry this level of traceability as a standard requirement.
• Production accreditation: Clinical supply is sourced from facilities operating under HACCP and BQUAL certification at minimum, with relevant offshore accreditations applicable to the destination market.

Honey X operates across all of these requirements for the buyer segments that need them. The documentation infrastructure exists. The accreditations are current. The testing is conducted per batch.

WA Jarrah Honey and Non-Peroxide Activity

WA Jarrah honey (Eucalyptus marginata) is particularly relevant to clinical supply because of its Non-Peroxide Activity (NPA) profile.

NPA is the stable component of honey's independently verified antimicrobial activity. Unlike Peroxide Activity, NPA is not dependent on hydrogen peroxide. The stability profile of NPA means it is maintained across storage conditions that would diminish peroxide-based activity over time.

This long-term stability is the reason NPA is the component of most direct relevance to clinical applications where shelf life and product integrity across the supply chain are procurement requirements. Manuka honey is well known for its NPA, linked to Methylglyoxal (MGO). WA Jarrah honey also carries meaningful NPA alongside PA, verified through the same WDPE methodology. For buyers already sourcing Manuka, WA Jarrah honey offers a complementary supply option with a distinct but equally rigorous bioactivity profile, as verified at Analytica (ALS).

Jarrah is available in grades from TA15 through TA55+. View the full active WA honey product range.

Supply Formats for Clinical Buyers

Honey X makes bulk honey supply available to clinical buyers in formats suited to clinical procurement volumes and downstream packaging requirements.

Bulk formats include 300kg drums and 1,400kg IBCs for high-volume clinical procurement, as well as 28kg pails and 14kg cubes for mid-volume or trial orders. Each format is available with batch-specific documentation and can be supplied under the certification basis required by the buyer's destination market.

For buyers who require honey in smaller or consumer-accessible formats, Honey X produces sachets across a full size range: 8g, 10g, 13g, 20g, 25g, and 30g. Jar and PET formats are also available. All formats are produced under HACCP-accredited production lines with full traceability back to batch.

Certification Basis

Honey X holds HACCP and BQUAL certification as the foundation of its quality system. BQUAL is the Australian honey industry's benchmark quality assurance programme and is the standard most relevant to clinical supply buyers in international markets who require an audited quality framework specific to honey production and handling.

Beyond these core certifications, Honey X holds 12+ certifications in total, including offshore accreditations for specific destination markets. Honey X is a registered importer for China, the UK, the USA, and Saudi Arabia, and the export documentation framework is designed to meet the requirements of clinical and regulatory buyers in each of these jurisdictions.

Certification documentation is available to approved buyers. View the Honey X contact page to enquire about certification specifics relevant to your market.

Heritage and Scientific Oversight

The Fewster family has been beekeeping in Western Australia since 1916, now in its fifth generation. The scientific oversight at Honey X is led by Mike Fewster, Chief Scientific Officer, who holds Bachelor's and Master's degrees in Applied Science and whose work underpins the Jarrah Factor™ grading system and all in-house screening protocols.

The combination of generational supply continuity and in-house scientific rigour is a meaningful distinction for clinical supply buyers who require confidence in both the consistency of supply and the accuracy of the documentation that accompanies it.

Over 200 tonnes of active WA honey have been tested across five independent laboratories. In-house screening is validated by those same independent laboratories. Every batch independently tested for activity, composition, and compliance before release.

Enquire About Clinical Supply Grading and Batch Documentation

If you are sourcing honey for a clinical supply chain and need to understand the TA grading available, the documentation standard, or the certification basis applicable to your market, the starting point is a direct conversation.

Honey X supplies buyers in 17+ markets from bulk drums and IBCs through to smaller packed formats. The testing, documentation, and traceability infrastructure is in place. The question is whether the specific grade, format, and certification basis you require is available for your destination market and volume.

View the active WA honey range, or enquire directly about clinical supply grading and batch documentation via the Honey X contact page.

The Market Case for Honey in Recovery and Rehydration Products

Product developers in active wellness and adjacent categories are moving away from synthetic ingredient lists toward natural ingredients with documented bioactive properties, a clean-label story, and verifiable supply chains.

Honey sits at the intersection of all three requirements. What makes it commercially relevant is not just the category positioning. It is the documented properties of specific honey varieties, and what those properties mean for product formulation at a technical level.

This post covers what the research indicates, which honey varieties are relevant to this product category, and how private label formulation through Honey X gives brand builders access to both the supply and the development capability to bring a credible product to market.

What the Research Indicates

Honey has been the subject of considerable research interest in the context of carbohydrate delivery and physical performance. The University of Memphis conducted a 64km cycling trial in which honey was found to perform comparably to synthetic carbohydrate gels as a fuel source across the duration of the event.

The carbohydrate profile of honey is a key reason for this. Honey is approximately 80% carbohydrates, composed of roughly 35 to 40% fructose and 30 to 35% glucose. This profile is relevant to product developers building in categories where carbohydrate delivery and dose are central formulation considerations.

Dose also matters. Research indicates that a 60g dose delivers a more meaningful response than a 30g dose. For sachet format decisions, this is a directly applicable data point. The 30g sachet format available through Honey X aligns with the higher end of the dose range indicated in the literature.

On the rehydration side, a study on Acacia honey found that participants who consumed honey before a second run covered approximately 10% farther compared to those who consumed water alone. This is a documented observation about performance across a second exercise bout. It is the kind of data point that product developers in this category need to understand when evaluating honey as a natural ingredient.

Why WA Honey Varieties Are Relevant to This Category

Not all honey is equivalent from a formulation standpoint. The bioactive compound profile varies significantly by botanical source, geography, and production method.

WA honey is produced in one of the world's most biosecure beekeeping environments. Over 80% of WA's honey-producing forests remain untouched by development. Beekeeping in WA is conducted without antibiotics, chemical treatments, or artificial feeding. This matters to product developers because it means the bioactive compound profile of the raw material is consistent and uncontaminated across supply.

Western Australian honey varieties, particularly Jarrah and Yarri (Blackbutt), carry meaningful polyphenol and flavonoid concentrations that have been verified through third-party testing. Yarri (Eucalyptus patens) is notably rich in antioxidant and antibacterial compounds. Jarrah (Eucalyptus marginata) carries high Non-Peroxide Activity alongside a documented antioxidant profile.

These are not marketing assertions. Honey X products are tested and third-party verified at Analytica (ALS), ChemCentre, and the University of Sydney. The 153+ third-party tests conducted across five independent laboratories provide the kind of documented evidence base that brand builders in regulated and semi-regulated product categories need to reference.

Jarrah Honey: The Low GI Base

Jarrah honey carries a low glycaemic index of 46, independently trialled and validated under the Glycemic Factor™ for the Jarrah TA50+ grade. This is a clinically trialled figure, not a category estimate. For product categories where GI positioning is commercially relevant, this is a formulation-level advantage with documented evidence behind it.

Jarrah's low GI is a product of its natural sugar composition. Its high fructose to glucose ratio results in slower glucose release, and it is the same compositional feature that prevents crystallisation, underpinning the Crystallisation-Free Guarantee™. For infused product development, a base that does not crystallise and carries a clinically trialled GI of 46 is a meaningful formulation asset.

Jarrah is available in grades from TA15 through TA55+, all independently tested under the Well-Diffusion Phenol Equivalent (WDPE) methodology. Read more on how WA honey performs as a performance ingredient in published data.

Sachet Format: The Right Delivery Format for This Category

Product format is as important as ingredient selection. Single-serve delivery is the established standard across active wellness and on-the-go product lines, and the sachet format is well suited to honey-based formulations.

Honey X produces sachets across a full range of sizes: 8g, 10g, 13g, 20g, 25g, and 30g, giving product developers genuine flexibility in dose and format design. Film is produced in PET/ALU/PET/PE/ALU construction with gravure printing, and up to five unique designs can be produced per film order.

The high-speed sachet line operates at up to 25,000 units per day. First order timelines run to 12 to 14 weeks. Repeat orders run to 4 to 6 weeks. Sachet products can also be packed into doy pouches (130mm x 50mm x 180mm, holding 10 sachets) for retail-ready or wholesale presentation.

Contract packing is available for buyers who hold their own honey supply and require a HACCP-accredited facility for production.

Custom Formulation Capability

The product opportunity in this category is not honey in a sachet in isolation. The most credible products combine honey with other natural ingredients to create a formulation that is both scientifically grounded and market-positioned for a specific context.

Honey X works with any raw natural bark, powder, or extract to develop custom infused formulations. The brief comes from the buyer. The development comes from the Honey X team.

The in-house team specialises in formulation and development at both a scientific and infusion level, and at the level of current trend and market fit across key regions, through to market entry positioning. A buyer does not need to arrive with a complete product specification. They need to arrive with a market need. The team's role is to close the gap between that need and a production-ready SKU that enters the market correctly.

This capability is not widely available in the honey supply industry. Most honey suppliers supply honey. Honey X supplies formulation, documentation, packing, compliance, and export-ready delivery. The difference is significant for brand builders operating in markets where consumer expectations around provenance, bioactivity, and clean-label formulation are high.

The Broader Market Opportunity

The global natural health product market was valued at USD 23.5 billion in 2023 and is projected to reach USD 38.5 billion by 2033, growing at a 5.3% compound annual growth rate. Within this market, bioactive honey occupies a growing segment that is underpinned by third-party testing data rather than category-level claims.

Brand builders who enter this category with a formulation built on verified WA honey have a differentiated story. That story holds in premium retail, foodservice formats, and export markets where provenance and supply chain documentation matter to buyers.

The Fewster family has been producing and exporting WA honey since 1916, now in its fifth generation. The supply consistency and scientific credibility behind the ingredient are backed by a 100-year operational track record and 153+ third-party test results across five laboratories.

Common Questions From Buyers in This Category

Can honey be used in rehydration product formulations? Honey has been studied in the context of exercise and fluid replacement. The Acacia honey study referenced in this post found participants covered approximately 10% farther in a second run compared to water. The carbohydrate profile of honey, approximately 80% carbohydrates with roughly 35 to 40% fructose and 30 to 35% glucose, is the basis on which formulation developers are exploring honey as a natural ingredient in this product category.

What makes WA honey relevant to product formulation in this space? WA honey varieties, particularly Jarrah and Yarri, carry documented polyphenol and flavonoid concentrations alongside a well-characterised carbohydrate profile, all verified through independent third-party testing. The clinically trialled GI of 46 for Jarrah Platinum TA50+ and the antioxidant capacity of Yarri are the primary formulation reasons WA honey is of interest to product developers in this category.

What dose format does the research support? The available data indicates 60g is more effective than 30g. Honey X sachet formats go up to 30g per serve, and product developers can consider multi-sachet protocols or the jar and PET formats for higher dose applications.

Enquire About Custom Formulation for Your Market

If you are developing a product in the active wellness or natural ingredient category and want to understand what WA honey can contribute at a formulation level, the starting point is a conversation with the Honey X team.

Honey X operates across 17+ markets and supplies buyers from bulk ingredient sourcing through to fully packed, export-compliant private label products. The team can advise on honey variety selection, dose format, ingredient compatibility, and market entry positioning relevant to your target region.

Enquire about custom formulation for your market, or view the active WA honey range to understand the ingredient options available.

What Custom Honey Formulation Actually Means

Honey X develops custom infused honey products for international buyers. The base is independently tested Western Australian active honey. The infusion layer is developed from raw natural ingredients sourced to the buyer's brief.

The process begins with a market need. A buyer comes to Honey X with a defined commercial objective: a target region, a target channel, and a product concept that does not yet exist as a production-ready SKU. The Honey X team develops the formulation from that brief.

This is not a catalogue selection. It is formulation work. The outcome is a verified, production-ready infused honey product built to specification, positioned for the market it is entering, and backed by independent test documentation from day one.

The Formulation Process: From Brief to Production-Ready SKU

Custom infusion development at Honey X follows a defined path from concept through to a production-ready SKU. The starting point is always the buyer's market brief, not a pre-existing ingredient list.

Once the brief is received, the team works with raw natural ingredients: barks, powders, roots, seeds, and botanical extracts. Formulation is developed at both the scientific and infusion level, with ingredient selection driven by the intended product attributes and the market the product is entering.

From there, the formulation moves through testing and verification before production is confirmed. Every infused product that leaves the Honey X facility is tested. Batch certificates are issued at production. The buyer receives a verified, documented product.

The Team Behind the Formulations

The in-house team at Honey X specialises in formulation and development at both a scientific and infusion level, and at the level of current trend and market fit across key regions, through to market entry positioning.

This is a deliberate combination. Formulation science without market intelligence produces products that perform technically but land incorrectly in the market. Market intelligence without formulation capability produces trend-led concepts that cannot be manufactured to specification. The Honey X team holds both.

The capability extends through to market entry positioning. When a buyer receives a production-ready SKU from Honey X, the product has been developed with the right formulation for the target market, the right format for the target channel, and the right positioning to enter that market correctly. Learn more about the Honey X team and its scientific background.

The Base: Why the Honey Matters Before the Infusion

Every custom infusion is built on a verified WA active honey base. The base is not a neutral carrier. It brings its own independently tested bioactivity into every formulation, and the choice of base is a formulation decision in itself.

Three bases are available for infused products. Each carries a distinct bioactive and compositional profile that shapes the formulation possibilities and the product story available to the buyer.

Jarrah (Eucalyptus marginata)

Jarrah carries high Non-Peroxide Activity (NPA), a low glycaemic index validated under the Glycemic Factor™ (GI of 46 for the TA50+ Platinum grade, clinically trialled), and a naturally non-crystallising profile backed by the Crystallisation-Free Guarantee™. The Crystallisation-Free Guarantee is Australia's first of its kind, underpinned by Jarrah's naturally high fructose to glucose ratio.

Jarrah does not crystallise because its glucose content is low relative to its fructose content, the same biochemistry that drives the low GI profile. For infused products entering markets where ingredient quality, glycaemic profile, and shelf stability are relevant product attributes, Jarrah is the primary base.

Available in grades from TA15 through TA55+. Honey X has verified Jarrah at TA55+ through independent third-party testing, representing the highest grade achieved in its supply. All grades are assigned on the basis of third-party WDPE testing at independent laboratories.

Marri (Corymbia calophylla)

Marri carries high Total Activity (TA) with strong peroxide-based bioactivity. Available at TA30+, it is independently tested and verified across production batches. For infused products where high TA is the primary base attribute, Marri provides a credible and well-documented foundation.

The peroxide-based activity in Marri is hydrogen peroxide-driven, activated by moisture. This mechanism is distinct from the NPA profile of Jarrah and gives Marri its own formulation identity within the infusion programme.

Forest Blend

Forest Blend is a multi-floral Western Australian honey that provides value positioning without compromising the provenance and biosecurity credentials of WA honey. For infused products where cost efficiency is a factor in the market brief, Forest Blend allows the buyer to retain a verified WA base at a more accessible price point.

All three bases are independently tested at Analytica (ALS), ChemCentre, and the University of Sydney. Every infusion inherits the documentation framework of the base it is built on. View the full active WA honey product range.

Why WA Honey Is the Right Foundation

The quality of the base matters before any infusion work begins. WA honey is produced in one of the world's most biosecure beekeeping environments. Over 80% of WA's honey-producing forests remain untouched by development. Beekeeping is conducted without antibiotics, chemical treatments, or artificial feeding.

This biosecurity profile directly affects the integrity of the raw material. The bioactive compound profile of WA active honey is consistent and uncontaminated because the production environment has not been subject to the agricultural pressures that affect honey supply in other regions. For infused product development, this consistency is a formulation-level advantage.

Honey X has conducted 153+ third-party tests across five independent laboratories and has tested over 200 tonnes of active WA honey. The supply chain documentation infrastructure that supports an infused product is built on this testing history.

Formats Available for Infused Products

Custom infused honey products are available across the full range of Honey X packaging formats. Format selection is part of the formulation brief and is determined by the target channel, the target buyer, and the market entry strategy.

Sachet formats are available in 8g, 10g, 13g, 20g, 25g, and 30g. Sachets are produced on high-speed or low-MOQ lines depending on the buyer's volume requirements, with daily capacity reaching 25,000 units on the high-speed line. The sachet format is produced in PET/ALU/PET/PE/ALU construction with gravure printing, and up to five unique designs can be produced per film order.

Jar formats are available for retail-facing and premium gifting applications. PET containers are available for buyers prioritising lightweight, shatter-resistant formats suited to export and online retail. All three formats support custom label and branding developed to the buyer's specifications.

Format decisions affect shelf positioning, freight costs, MOQ requirements, and how the product is perceived at point of sale. These are part of the market entry discussion from the start. Honey X contract packing services support buyers who bring their own supply and require a licensed, accredited packing facility.

Testing and Verification: What Every Infused Batch Carries

Every infused product developed and packed by Honey X is tested and verified before release. Batch certificates are issued for each production run and are available to wholesale buyers through the customer portal.

The testing framework covers the integrity of the base honey, the stability of the infused formulation, and compliance with food safety and export standards. Honey X holds HACCP and BQUAL certification, with additional offshore accreditations for specific export markets.

For buyers entering regulated markets, the documentation package available from Honey X is designed to support market entry compliance from day one. This includes not just the batch certificate but the full traceability chain from source to production.

Heritage and Scientific Credibility

The Fewster family has been beekeeping in Western Australia since 1916, now in its fifth generation. That heritage is not a marketing backdrop. It is a supply continuity story backed by over 100 years of operational consistency in one of the world's most distinctive honey-producing regions.

Mike Fewster, Chief Scientific Officer, holds Bachelor's and Master's degrees in Applied Science and has decades of experience in chemistry and analytical methods. His work underpins the Jarrah Factor™ grading system and all in-house screening protocols at Honey X.

The Fewster family's commitment to antibiotic-free, residue-tested supply, combined with independent third-party verification across five laboratories, is what gives every infused Honey X product its documentation foundation. Learn more about the people and science behind Honey X.

What Honey X Does Not Formulate

Custom formulation at Honey X is built on a clear set of operational principles. Honey X does not work with synthetic ingredients, artificial additives, or artificial flavour compounds. Every infusion is built from raw natural materials. This is not a marketing position. It is an operational boundary that ensures the integrity of the base honey is not compromised by the infusion layer.

Honey X also does not produce commodity formulations for price-led markets. The custom infusion service exists for buyers building differentiated products in channels where provenance, ingredient integrity, and independent verification matter.

The distinction matters because it defines the category of buyer this capability serves and the category of market it is designed for. Private label services at Honey X are built on the same principles: verified base, documented supply, and a product designed to compete on quality.

What Buyers Engage Honey X For

The buyers who engage Honey X for custom infusion development share a consistent profile. They have identified a market opportunity. They understand what their target buyer is looking for. They need a team that can translate a market brief into a production-ready, verified, positioned product.

Some buyers arrive with a detailed brief. Others arrive with a market insight and need the formulation conversation to define the product concept. Both approaches work. The Honey X team is equipped to take a buyer from a market need through to a finished SKU regardless of how defined the brief is at the starting point.

What buyers do not receive from this service is a catalogue to choose from. The capability is real. The formulations are developed to specification. Specific formulation work that has already been completed remains confidential to the buyers it was developed for. That boundary is part of what makes this service worth engaging. Explore the active WA honey bases that underpin every custom infusion.

Enquire About Custom Infusion Development

Honey X takes a limited number of custom infusion development briefs. The service is designed for buyers who are serious about entering a market with a product that is built correctly, tested thoroughly, and positioned to compete.

Tell us your market, your format, and your target buyer. The team will review your brief and respond with what is possible.

Enquire about custom infusion development through the Honey X private label and formulation service page. For buyers with existing honey supply requiring production and packing, contract packing services are available separately. All enquiries are reviewed before access to formulation capability and pricing is provided.

Low GI Honey: Why Product Developers Are Paying Attention

Glycemic index has moved from a niche nutritional concept to a mainstream product attribute. In specialty retail channels across multiple export markets, low GI labelling on food products is no longer a differentiation play. It is increasingly an expectation.

For product developers sourcing honey as an ingredient, this creates a specific question: which honeys actually have clinically verified low GI data, and what does that data make possible at the formulation and label level?

This post addresses that question with reference to active Western Australian honey, specifically Jarrah, and explains what the Glycemic Factor™ validation system means in practice for buyers building products in GI-aware categories.

What GI Measures and Why It Matters for Formulation

The glycemic index is a numerical scale measuring how quickly a carbohydrate-containing food raises blood glucose relative to pure glucose. Foods below 55 are classified as low GI. Foods between 56 and 69 are medium. Foods at 70 and above are high GI.

Honey, as a category, is not automatically low GI. Most commercial honeys sit in the medium to high range depending on their sugar composition. What separates Jarrah honey from the broader category is the biochemistry that drives a low GI result, and the independent testing data that validates it.

For a product developer, a verified GI figure is not just a marketing asset. It is a formulation decision point. The GI of the primary ingredient interacts with everything else in the product: the serve size, the delivery format, the dose, and the label claims that are available in the target market.

The GI of Jarrah Honey

Jarrah Platinum TA50+ has a clinically trialled glycemic index of 46. This places it in the low GI category, well below the 55 threshold.

This is not an estimated figure derived from sugar composition modelling. It is a result from clinical GI testing conducted under standardised methodology. The distinction matters for buyers who need to substantiate a low GI position in their target market. An independently tested GI result is documentable and defensible. An estimate is neither.

Batch-specific GI test certificates are available to registered wholesale buyers through the Honey X customer portal. Formulators can access the underlying methodology, the testing facility credentials, and the batch reference before committing to a formulation direction.

The Glycemic Factor™: What the Validation System Covers

The Glycemic Factor™ is Honey X's proprietary validation system for assessing and communicating the low GI profile of Jarrah honey. It is the framework through which GI testing is commissioned, results are verified, and the claim is positioned for commercial use by buyers.

The Glycemic Factor is not a marketing label. It represents a defined process: independent clinical testing, batch-level verification, and a repeatable methodology that allows buyers to confidently position products in categories where glycemic response is a purchase driver.

For buyers building in health food, wellness, or specialty retail channels, the Glycemic Factor provides the verification layer needed to substantiate a low GI position at the product level. Learn more about the science and testing framework at the Honey X About page.

The Biochemistry Behind the Low GI Result

Honey's glycemic response is largely determined by its ratio of glucose to fructose. Glucose is absorbed rapidly and drives a fast blood sugar rise. Fructose is metabolised hepatically and produces a lower glycemic response.

Jarrah honey has a naturally low glucose to fructose ratio. Fructose is the dominant sugar. This composition is intrinsic to the Jarrah species and consistent across verified batches. It is not a processing outcome or the result of any additive intervention.

The low glucose to fructose ratio also explains a separate commercial property of Jarrah honey: it does not crystallise. Crystallisation in honey is driven by glucose precipitating around particles. Because Jarrah is fructose-dominant, it remains liquid over time. The Crystallisation-Free Guarantee™ is built on the same underlying chemistry as the low GI result. Both properties trace back to a single structural feature of the honey.

This connection matters for product developers. The low GI profile and the non-crystallising property are not independent claims that need to be justified separately. They are expressions of the same biochemical composition, backed by the same independently verified testing data.

Jarrah and the Broader Bioactive Profile

Low GI is one part of the Jarrah honey profile. It does not exist in isolation from the other verified attributes that make Jarrah the dominant grade in Honey X's export volume: 73% of export volume is Jarrah by grade.

Jarrah Platinum TA50+ combines a clinically trialled GI of 46 with high Non-Peroxide Activity (NPA) and verified antimicrobial strength at the TA50+ grade. The Jarrah Factor™ is the composite quality score that brings these attributes together: antimicrobial strength, antioxidant levels, and sugar composition combined into a single grade designation. TA grades run from TA15 through TA55+, the highest grade verified in supply.

For a product developer, this means the base ingredient brings multiple verified attributes into the formulation simultaneously. The low GI profile can be positioned alongside provenance, bioactivity, and shelf stability rather than as a standalone claim. This combination is what separates Jarrah from honeys that may share a similar GI result without the broader test history.

For the science behind Jarrah's antimicrobial profile, see the Jarrah antimicrobial science framework.

What the Data Makes Possible for Product Developers

A verified GI of 46 opens specific positioning options for buyers building product ranges. The key word is positioning. The data creates options. How those options are applied depends on the target market, the regulatory environment, and the brand's broader communication strategy.

In markets where low GI labelling is accepted and recognised by the relevant food standards authority, an independently tested GI result is the basis for a factual on-pack statement. In markets where the low GI certification symbol is used, formal registration through the relevant programme is required.

What the data does not support, in any market, is language that moves from a factual GI statement into a therapeutic claim. Describing a product as appropriate for specific health conditions or implying a clinical outcome is regulated differently and requires separate substantiation. The GI score is a food composition measurement. It describes how the ingredient behaves, not what it treats.

Honey X recommends that buyers working on low GI label claims engage their local regulatory adviser before finalising on-pack copy. The test certificates Honey X provides give the data foundation. Application of that data is a regulatory decision for the specific market. The private label programme is structured to support this process from the outset.

Who Is Sourcing on the Basis of GI

The buyers requesting GI data from Honey X tend to fall into a consistent set of categories.

Health food brands building speciality ranges where glycemic awareness aligns with a broader positioning around natural, minimally processed ingredients. These buyers want low GI as a product attribute alongside other verified nutritional characteristics, not as the sole differentiator.

Specialty retail buyers in markets where category management actively separates products by GI rating. In these channels, a verified GI claim can determine whether a product sits in a standard grocery set or a specialist health category. The difference in placement has a measurable effect on volume and margin.

Export buyers in markets across North Asia, the UK, and Southeast Asia where premium WA honey is already an established category and low GI data adds a specific, documentable attribute to the product story.

All of these buyers share one requirement: the data needs to be independently verified and available at the batch level. General category statements are not sufficient for buyers building compliant product ranges. Batch-level documentation is what makes the claim usable.

Accessing GI Data as a Wholesale Buyer

Batch-specific GI test certificates for Jarrah Platinum TA50+ are available to registered wholesale buyers. These documents include the full testing methodology, the testing facility credentials, and the batch reference for traceability.

Access is through the Honey X customer portal after wholesale registration and approval. This applies to GI certificates, TA test results, and all third-party quality documentation. Over 153 third-party tests have been conducted across five independent laboratories: Analytica (ALS), ChemCentre, the University of Sydney, QSI GmbH, and NMI.

Honey X has verified 200+ tonnes of active Western Australian honey across these laboratories. The testing framework is designed to give buyers at every level the documentation they need to build compliant, positioned products. View the active WA honey product categories for grade specifications.

Summary: What Product Developers Need to Know

• Jarrah Platinum TA50+ has a clinically trialled GI of 46, placing it in the low GI category
• The result is independently tested, not modelled from composition data
• The Glycemic Factor™ is Honey X's validation system for managing and communicating this result at the batch level
• The biochemical driver is Jarrah's naturally low glucose to fructose ratio: the same chemistry behind the Crystallisation-Free Guarantee™
• Low GI label claims are supportable where independently tested GI results are accepted by the target market's regulatory framework
• Batch-specific test certificates are available to registered wholesale buyers
• Language that implies therapeutic outcomes requires separate regulatory advice for the specific target market

Enquire about private label and formulation options for low GI honey products, or learn more about the science and testing framework behind Honey X's product range.